Lupin stock soars: Analysts bullish on growth but valuation may cap upside

Lupin's stock surged as analysts remain optimistic about its growth prospects, driven by strong quarterly results and robust product pipeline. However, high valuations could limit further upside potential. Investors are advised to monitor the company's execution and market conditions closely. The pharmaceutical sector is gaining traction with increasing demand for generics and biosimilars globally, positioning Lupin for continued success.